49 Predicting risk of scd in fabry disease: a single centre experience. (5th June 2017)

• Record Type: Journal Article
• Authors: Baig, Shanat; Edwards, Nicky; Nordin, Sabrina; Liu, Boyang; Moon, James; Geberhiwot, Tarek; Steeds, Richard P
• Is Part Of: Heart. Volume 103(2017)Supplement 5
• Page Start: A38
• Page End: A39
• Publication Date: 2017-06-05
• Subjects: Fabry Disease -- Sudden cardiac death -- Ventricular arrythmia; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2017-311726.48
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Introduction: Fabry disease (FD) is a rare X-linked lysosomal storage disorder with a variable cardiac phenotype and a defined risk of ventricular arrhythmia (VA) and sudden cardiac death (SCD). To-date however, there is no accepted tool for risk prediction in FD and the ESC calculator in hypertrophic cardiomyopathy specifically excludes lysosomal storage diseases. Data on the prevalence of VA and SCD are restricted to single centre studies and registry data. These have identified individual risk factors including age, QRS duration>120 ms, left atrial dilatation (LA), late gadolinium enhancement on cardiac magnetic resonance (CMR) imaging (LGE), and left ventricular hypertrophy (LVH). The aim of this study was to assess the prevalence of these risk factors in a Regional FD centre and to examine known markers associated with increased cardiac mortality in FD to comprehensively assess risk. Methods: This was a retrospective cross sectional observational study of patients with a proven diagnosis of FD (genetic and clinical markers) attending the Regional Centre for Rare Diseases in Birmingham between 2012–16. As part of routine annual assessment, patients underwent 12-lead ECG, 24 hour holter monitoring, transthoracic echocardiography and multi-parametric CMR. The cohort was divided into 2 groups: 1) a high risk group defined by presence of either VA (≥3 consecutive ventricular beats at a rate ≥120 beats per minute) or SCD; 2) all other patients. In addition to the above 5 risk factors, genotype (cardiac variant v non-cardiac variant), high sensitivity troponin (HS Tn) and NT pro-B natriuretic peptide were included. The frequency and significance of each of these proposed risk factors was studied. Fisher's exact test was used to perform statistical analysis. Results: In total 57 patients (male gender 42%, age mean 47±18 years.) were studied, of whom 13 patients had a documented VA and 2 patients suffered SCD. 11/13 in high risk group were on ERT (7±6 years.) and 21/44 in the remainder (6±3.8 years.). Identified risk factors and prevalence are outlined in Table 1. Male gender, age>50, LVH, LGE, QRS>120 ms were all more frequent in those with VA or SCD but risk was also associated with increased HS Tn and NT pro-BNP. The presence of a cardiac variant genotype did not appear to influence risk. Outcome: These data confirm specific demographic, electrical and structural risk factors for VA and SCD in FD, although these are also present in those without arrhythmic events. Large multi-centre prospective studies are needed to further define the relative importance of these risk factors and their potential inter-relationship.